Cargando…

A gut microbiota score predicting acute graft‐versus‐host disease following myeloablative allogeneic hematopoietic stem cell transplantation

Although studies have reported that intestinal microbiota are associated with acute graft‐versus‐host disease (aGVHD), they lacked a satisfactory method for predicting aGVHD. We collected stool and blood samples at day 15 posttransplant from 150 patients from two centers who underwent myeloablative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Lijie, Zhao, Ke, Li, Yuanyuan, Han, Haohao, Zhou, Lizhi, Ma, Ping, Fan, Zhiping, Sun, Hui, Jin, Hua, Jiang, Zhongxing, Liu, Qifa, Peng, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154648/ https://www.ncbi.nlm.nih.gov/pubmed/31605563 http://dx.doi.org/10.1111/ajt.15654

Ejemplares similares

Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation
por: Han, Lijie, et al.
Publicado: (2022)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Applications of gut microbiota in patients with hematopoietic stem-cell transplantation
por: Yu, Jifeng, et al.
Publicado: (2020)

Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients
por: Han, Lijie, et al.
Publicado: (2018)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Yang, Kaibo, et al.
Publicado: (2020)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Sirolimus and Mycophenolate Mofetil as Graft-versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation
por: Johnston, L, et al.
Publicado: (2011)

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
por: Park, Bo-Kyoung, et al.
Publicado: (2018)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation
por: Goh, Ri-Young, et al.
Publicado: (2011)

Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease
por: van Lier, Yannouck F., et al.
Publicado: (2023)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

P1269: PRIMARY GRAFT FAILURE INCIDENCE, RISK FACTORS, AND OUTCOMES IN PATIENTS UNDERGOING NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE
por: Mata, Jonaphine, et al.
Publicado: (2023)

Microbiota Predict Infections and Acute Graft-Versus-Host Disease After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation
por: Margolis, Elisa B, et al.
Publicado: (2023)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft vs host disease
por: Le Bastard, Quentin, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein–Barr virus infection
por: Luo, Yanhui, et al.
Publicado: (2022)

The Butyrogenic and Lactic Bacteria of the Gut Microbiota Determine the Outcome of Allogenic Hematopoietic Cell Transplant
por: Devaux, Christian Albert, et al.
Publicado: (2020)

Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Heidrich, Vitor, et al.
Publicado: (2021)

Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation
por: Park, Joo Han, et al.
Publicado: (2014)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS
por: Kok, Laurence M. C., et al.
Publicado: (2019)

Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2021)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Immune Reconstitution and Graft-Versus-Host Reactions in Rat Models of Allogeneic Hematopoietic Cell Transplantation
por: Zinöcker, Severin, et al.
Publicado: (2012)

Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
por: Nassar, Amr, et al.
Publicado: (2014)

Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease
por: Tijaro-Ovalle, Natalia M., et al.
Publicado: (2019)

Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation
por: Simonetta, Federico, et al.
Publicado: (2017)

Gut microbiota and allogeneic transplantation
por: Wang, Weilin, et al.
Publicado: (2015)

Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation
por: Lin, Ren, et al.
Publicado: (2013)

Graft conditioning with fluticasone propionate reduces graft‐versus‐host disease upon allogeneic hematopoietic cell transplantation in mice
por: Varady, Erika S, et al.
Publicado: (2023)

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
por: Campbell, P, et al.
Publicado: (2014)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation
por: Severyn, Christopher J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n62u1id5m8s421dl6pajh0u0f5